Abstract
Takayasu arteritis (TAK) is a rare vasculitis that often affects young women of childbearing age, and its management during pregnancy poses unique challenges. Limited data exist regarding the safety and efficacy of tocilizumab (TCZ), an interleukin-6 receptor antagonist, in the treatment of TAK during pregnancy. This case report presents a unique and valuable insight into the use of TCZ in pregnant patients with TAK. We report an 18-year-old female patient with TAK who was treated with TCZ during two pregnancies, resulting in positive maternal and neonatal outcomes. However, a newly identified descending aortic aneurysm was noted after the second delivery, highlighting the importance of careful monitoring of vascular lesions in patients with TAK receiving TCZ. Our findings suggest that TCZ has a high safety profile for both the mother and fetus; however, further research and close monitoring are essential for its use in pregnant patients with TAK.